Chemokine expression in coronary circulation after coronary angioplasty as a prognostic factor for restenosis

Y Hojo1, U Ikeda, T Katsuki

  • 1Department of Cardiology, Jichi Medical School, Minamikawachi-machi, Tochigi 329-0498, Japan.

Atherosclerosis
|May 23, 2001
PubMed

Insights

Percutaneous transluminal coronary angioplasty (PTCA) increases macrophage-colony stimulating factor (M-CSF) in coronary circulation. Elevated M-CSF levels after PTCA correlate with restenosis, suggesting its role in neointima formation.

Area of Science:

  • Cardiovascular Medicine
  • Immunology
  • Biochemistry

Background:

  • Chemokines are implicated in cardiovascular diseases, including atherosclerosis and restenosis post-angioplasty.
  • Understanding chemokine expression changes after percutaneous transluminal coronary angioplasty (PTCA) is crucial for managing cardiovascular complications.

Purpose of the Study:

  • To investigate alterations in coronary chemokine expression following PTCA.
  • To determine the clinical significance of these chemokine changes, particularly in relation to restenosis.

Main Methods:

  • Studied 40 angina pectoris patients undergoing elective PTCA for left coronary artery stenosis.
  • Collected coronary sinus blood samples pre-PTCA, and at immediate, 4-hour, and 24-hour post-PTCA.
  • Measured plasma levels of interleukin-8 (IL-8), macrophage-colony stimulating factor (M-CSF), and monocyte chemoattractant protein-1 (MCP-1) using ELISA.

Main Results:

  • Plasma M-CSF levels significantly increased 4 and 24 hours post-PTCA.
  • No significant changes in plasma MCP-1 levels were observed within 24 hours post-PTCA.
  • Immunoreactive IL-8 was undetectable in all samples.
  • Higher M-CSF levels 24 hours post-PTCA correlated positively with late loss index and were significantly elevated in patients with restenosis.

Conclusions:

  • PTCA induces increased M-CSF levels in the coronary circulation.
  • Elevated M-CSF post-PTCA may contribute to neointima formation and restenosis by activating mononuclear phagocytes in injured vessels.

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...